Imaginostics Awarded $915k NIH-NIA SBIR Grant for Clinical Validation its Novel MRI biomarkers in Screening and Quantification of Dementia
Imaginostics received a notice of award on September 15th, 2022, under the Small Business Innovation Research (SBIR) program to support a Phase I study entitled, “Validation of a Novel Magnetic Resonance Imaging (MRI) Technology for both Diagnostic Screening and Quantification of Brain Vascular Physiology in Alzheimer’s-Disease-Related Dementias.” Imaginostics is thrilled to be starting a pivotal clinical study at Brigham and Women’s Hospital (BWH) this Fall. The 96-subject study will test the ability to detect dementia early in patients with Mild Cognitive Impairment (MCI). A second arm of the study will test the ability to characterize an individual’s patients with Vascular Dementia (VaD).
About Imaginostics:
Imaginostics, Inc., is a Boston-based longevity startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com
Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R43AG079732. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.